Insider Buying: Century Therapeutics (NASDAQ:IPSC) CEO Acquires 52,000 Shares of Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) CEO Brent Pfeiffenberger acquired 52,000 shares of the stock in a transaction that occurred on Friday, December 12th. The stock was acquired at an average cost of $0.58 per share, with a total value of $30,160.00. Following the completion of the purchase, the chief executive officer owned 3,322,990 shares of the company’s stock, valued at $1,927,334.20. This trade represents a 1.59% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Brent Pfeiffenberger also recently made the following trade(s):

• On Wednesday, November 19th, Brent Pfeiffenberger acquired 35,000 shares of Century Therapeutics stock. The shares were acquired at an average cost of $0.50 per share, for a total transaction of $17,500.00.
• On Monday, November 17th, Brent Pfeiffenberger sold 32,456 shares of Century Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $14,605.20.
• On Monday, November 17th, Brent Pfeiffenberger sold 32,456 shares of Century Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $14,605.20.

Century Therapeutics Trading Up 8.8%

Shares of NASDAQ:IPSC traded up $0.05 on Tuesday, reaching $0.62. The company had a trading volume of 1,160,469 shares, compared to its average volume of 791,483. The firm has a market capitalization of $54.41 million, a PE ratio of -1.95 and a beta of 1.80. Century Therapeutics, Inc. has a 52-week low of $0.34 and a 52-week high of $1.19. The firm’s 50 day simple moving average is $0.55 and its 200-day simple moving average is $0.55.

Century Therapeutics (NASDAQ:IPSC) last announced its earnings results on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 10.01%. As a group, equities research analysts predict that Century Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Leerink Partners reissued a “market perform” rating and issued a $2.00 price objective (down previously from $7.00) on shares of Century Therapeutics in a research report on Monday, November 17th. Leerink Partnrs downgraded Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Century Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 20th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.40.

Institutional Trading of Century Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its stake in shares of Century Therapeutics by 109.1% in the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after buying an additional 34,466 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Century Therapeutics by 26.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after acquiring an additional 38,052 shares during the last quarter. Prudential Financial Inc. purchased a new position in Century Therapeutics in the 2nd quarter worth approximately $25,000. Qube Research & Technologies Ltd purchased a new position in Century Therapeutics in the 2nd quarter worth approximately $38,000. Finally, AQR Capital Management LLC boosted its holdings in shares of Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after purchasing an additional 86,875 shares during the last quarter. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.